帕博利珠单抗一线治疗顺铂不耐受晚期尿路上皮癌(KEYNOTE-052):老年患者按年龄和体能状态分组的结局
KEYNOTE-052研究评估了帕博利珠单抗一线治疗顺铂不耐受晚期尿路上皮癌老年患者的安全性和抗肿瘤活性。在≥65岁、≥75岁及合并ECOG PS2的亚组中,客观缓解率分别为29%、27%、29%和31%,缓解持续时间与总生存期在各亚组间一致。结论认为无论年龄和体能状态如何,帕博利珠单抗的临床获益一致。
要点
- ≥65岁和≥75岁亚组的ORR分别为29%和27%。
- ≥65岁+ECOG PS2和≥75岁+ECOG PS2亚组的ORR分别为29%和31%。
- 各亚组间中位缓解持续时间和总生存期一致。
核心结论
- 帕博利珠单抗在晚期尿路上皮癌中的临床获益似乎不受年龄和/或较差体能状态影响。
研究设计与样本
- KEYNOTE-052(NCT02335424)是一项开放标签研究,纳入顺铂不耐受、初治、局部晚期/转移性尿路上皮癌且ECOG PS0-2的患者。
- 分析亚组包括≥65岁(n=302)、≥75岁(n=179)、≥65岁+ECOG PS2(n=119)和≥75岁+ECOG PS2(n=78)。
- 所有患者接受帕博利珠单抗200mg静脉注射每3周一次,直至确认进展、不可耐受毒性、患者退出或治疗24个月。
主要发现
- ≥65岁、≥75岁、≥65岁+ECOG PS2和≥75岁+ECOG PS2亚组的ORR分别为29%、27%、29%和31%。
- 上述亚组的完全缓解率分别为9%、5%、6%和6%,部分缓解率分别为20%、22%、23%和24%。
- 中位缓解持续时间和总生存期在≥65岁与≥65岁+ECOG PS2亚组间、以及≥75岁与≥75岁+ECOG PS2亚组间保持一致。
关键数值与推荐
- 主要终点为按RECIST v1.1评估的客观缓解率(ORR)。
- 关键次要终点包括总生存期(OS)、缓解持续时间(DOR)和安全性。
临床怎么用
- 对于顺铂不耐受的晚期尿路上皮癌老年患者,包括ECOG PS2者,帕博利珠单抗一线治疗可考虑作为有效选择。
局限性
- 研究为开放标签设计,缺乏对照组。
- 分析为事后探索性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with treatment-naive advanced urothelial cancer (UC) ineligible for cisplatin-based chemotherapy are typically older and have comorbidities, representing a difficult-to-treat population. OBJECTIVE: To evaluate the safety and antitumor activity of first-line pembrolizumab in subgroups of cisplatin-ineligible older patients (aged ≥65 and ≥75 yr) with advanced UC in KEYNOTE-052 (NCT02335424), including those with poor performance status (Eastern Cooperative Oncology Group performance status score 2 [ECOG PS2]). DESIGN, SETTING, AND PARTICIPANTS: Patients were cisplatin ineligible, had treatment-naive, histologically/cytologically confirmed, locally advanced/metastatic UC with measurable disease (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1]), and had ECOG PS0-2. Patient subgroups analyzed were aged ≥65yr (n = 302), ≥75 yr (n = 179), ≥65yr with ECOG PS2 (≥65yr+ECOG PS2; n = 119), and ≥75 yr+ECOG PS2 (n = 78). INTERVENTION: All patients received pembrolizumab 200mg intravenously every 3 wk until confirmed progression, intolerable toxicity, patient withdrawal, or 24 mo of therapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was objective response rate (ORR) as per RECIST v1.1. The key secondary endpoints were overall survival (OS), duration of response (DOR), and safety. RESULTS AND LIMITATIONS: ORRs for the ≥65yr, ≥75 yr, ≥65yr+ECOG PS2, and ≥75 yr+ECOG PS2 subgroups were 29%, 27%, 29%, and 31%, respectively; rates of complete and partial responses were similar across subgroups (9%, 5%, 6%, and 6%, and 20%, 22%, 23%, and 24%, respectively). Median DOR and OS were also consistent across the ≥65yr and ≥65yr+ECOG PS2 subgroups and the ≥75 yr and ≥75 yr+ECOG PS2 subgroups. Study limitations included open-label design, lack of a comparator group, and nature of post hoc exploratory analysis. CONCLUSIONS: The clinical benefit of pembrolizumab in advanced UC appeared to be consistent regardless of age and/or poor performance status. PATIENT SUMMARY: This study looked at whether older age and poorer performance status affect how well patients with previously untreated advanced urothelial cancer ineligible for standard-of-care treatment respond to pembrolizumab. Outcomes with pembrolizumab were not affected by older age or poorer performance status, making it an effective option.
引用
- Grivas P, Plimack ER, Balar AV, et al. Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status. Eur Urol Oncol. 2020. PMID: 32423837. doi:10.1016/j.euo.2020.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。